In vitro inhibitory activities of magnolol against Candida spp.

References

• GuineaJGlobal trends in the distribution of Candida species causing candidemiaClin Microbiol Infect201420Suppl 6 5 10
   Web of Science ®Google Scholar
• CalderoneRAIntroduction and historical perspectivesCalderoneRACandida and CandidiasisWashington, DCASM Press2002 3 13
   Google Scholar
• OddsFCBrownAJGowNAAntifungal agents: mechanisms of actionTrends Microbiol2003116 272 27912823944
   PubMed Web of Science ®Google Scholar
• WhiteTCMarrKABowdenRAClinical, cellular, and molecular factors that contribute to antifungal drug resistanceClin Microbiol Rev1998112 382 4029564569
   PubMed Web of Science ®Google Scholar
• EnwuruCAOgunledunAIdikaNFluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, NigeriaAfr Health Sci200883 142 14819357740
   PubMed Web of Science ®Google Scholar
• DiekemaDArbefevilleSBoykenLKroegerJPfallerMThe changing epidemiology of healthcare-associated candidemia over three decadesDiagn Microbiol Infect Dis2012731 45 4822578938
   PubMed Web of Science ®Google Scholar
• PfallerMARhombergPRMesserSAJonesRNCastanheiraMIsavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesDiagn Microbiol Infect Dis2015824 303 31325986029
   PubMed Web of Science ®Google Scholar
• YingYZhangJHuangSBFluconazole susceptibility of 3,056 clinical isolates of Candida species from 2005 to 2009 in a tertiary-care hospitalIndian J Med Microbiol2015333 413 41526068346
   PubMed Web of Science ®Google Scholar
• EggimannPGarbinoJPittetDEpidemiology of Candida species infections in critically ill non-immunosuppressed patientsLancet Infect Dis2003311 685 70214592598
   PubMed Web of Science ®Google Scholar
• HornDLNeofytosDAnaissieEJEpidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registryClin Infect Dis20094812 1695 170319441981
   PubMed Web of Science ®Google Scholar
• FaggiEPiniGCampisiEMartinelliCDifonzoEDetection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus infected and non-infected patients and in a yeast culture collectionMycoses2005483 211 21515842340
   PubMed Web of Science ®Google Scholar
• PontónJRüchelRClemonsKVEmerging pathogensMed Mycol200038Suppl 1 225 236
   PubMed Web of Science ®Google Scholar
• González GravinaHGonzález de MoránEZambranoOOral Candidiasis in children and adolescents with cancer. Identification of Candida sppMed Oral Patol Oral Cir Bucal2007126 E419 E42317909505
   PubMedGoogle Scholar
• NakayamaHIzutaMNakayamaNArisawaMAokiYDepletion of the squalene synthase (ERG9) gene does not impair growth of Candida glabrata in miceAntimicrob Agents Chemother2000449 2411 241810952588
   PubMed Web of Science ®Google Scholar
• PereaSLópez-RibotJLWickesBLMolecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasisAntimicrob Agents Chemother2002466 1695 170312019078
   PubMed Web of Science ®Google Scholar
• ChunchanurSKNadgirSDHaleshLHPatilBSKausarYChandrasekharMRDetection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patientsIndian J Pathol Microbiol2009524 501 50419805956
   PubMed Web of Science ®Google Scholar
• BaeEAHanMJKimNJKimDHAnti-Helicobacter pylori activity of herbal medicinesBiol Pharm Bull1998219 990 9929781854
   PubMed Web of Science ®Google Scholar
• BangKHKimYKMinBSAntifungal activity of magnolol and honokiolArch Pharm Res2000231 46 4910728656
   PubMed Web of Science ®Google Scholar
• ChangBLeeYKuYBaeKChungCAntimicrobial activity of magnolol and honokiol against periodontopathic microorganismsPlanta Med1998644 367 3699619121
   PubMed Web of Science ®Google Scholar
• SunLLiaoKWangDEffects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicansPLoS One2015102 e011769525710475
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory StandardsReference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second EditionWayne, PANational Committee for Clinical Laboratory Standards1997
   Google Scholar
• JinYYipHKSamaranayakeYHYauJYSamaranayakeLPBiofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infectionJ Clin Microbiol2003417 2961 296712843027
   PubMed Web of Science ®Google Scholar
• RamageGVande WalleKWickesBLLópez-RibotJLStandardized method for in vitro antifungal susceptibility testing of Candida albicans biofilmsAntimicrob Agents Chemother2001459 2475 247911502517
   PubMed Web of Science ®Google Scholar
• KuribaraHKishiEKimuraMWeintraubSTMaruyamaYComparative assessment of the anxiolytic-like activities of honokiol and derivativesPharmacol Biochem Behav2000673 597 60111164091
   PubMed Web of Science ®Google Scholar
• LinYRChenHHLinYCKoCHChanMHAntinociceptive actions of honokiol and magnolol on glutamatergic and inflammatory painJ Biomed Sci200916 9419832997
   PubMed Web of Science ®Google Scholar
• KoCHChenHHLinYRChanMHInhibition of smooth muscle contraction by magnolol and honokiol in porcine tracheaPlanta Med2003696 532 53612865972
   PubMed Web of Science ®Google Scholar
• ChenLCLiuYCLiangYCHoYSLeeWSMagnolol inhibits human glioblastoma cell proliferation through upregulation of p21/Cip1J Agric Food Chem20095716 7331 733719645506
   PubMed Web of Science ®Google Scholar
• ParkJLeeJJungEIn vitro antibacterial and anti-inflammatory effects of honokiol and magnolol against Propionibacterium spEur J Pharmacol20044961–3 189 19515288590
   PubMed Web of Science ®Google Scholar
• YangYLLoHJMechanisms of antifungal agent resistanceJ Microbiol Immunol Infect2001342 79 8611456364
   PubMedGoogle Scholar
• XiangMJLiuJYNiPHErg11 mutations associated with azole resistance in clinical isolates of Candida albicansFEMS Yeast Res2013134 386 39323480635
   PubMed Web of Science ®Google Scholar
• VermitskyJPSelfMJChadwickSGSurvey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detectionJ Clin Microbiol2008464 1501 150318305136
   PubMed Web of Science ®Google Scholar
• CorselloSSpinilloAOsnengoGAn epidemiological survey of vulvovaginal candidiasis in ItalyEur J Obstet Gynecol Reprod Biol20031101 66 7212932875
   PubMed Web of Science ®Google Scholar
• RichterSSGalaskRPMesserSAHollisRJDiekemaDJPfallerMAAntifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent casesJ Clin Microbiol2005435 2155 216215872235
   PubMed Web of Science ®Google Scholar
• KauffmanCACandiduriaClin Infect Dis200541Suppl 6 S371 S37616108001
   PubMed Web of Science ®Google Scholar
• FidelPLJrVazquezJASobelJDCandida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicansClin Microbiol Rev1999121 80 969880475
   PubMed Web of Science ®Google Scholar
• PfallerMAJonesRNCastanheiraMRegional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006–2011Mycoses20145710 602 61124863164
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJGibbsDLGlobal Antifungal Surveillance GroupCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005J Clin Microbiol2008462 515 52118077633
   PubMed Web of Science ®Google Scholar
• BadieePAlborziADavarpanahMAShakibaEDistributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patientsArch Iran Med2010134 282 28720597560
   PubMed Web of Science ®Google Scholar
• ThompsonGR3rdPatelPKKirkpatrickWROropharyngeal candidiasis in the era of antiretroviral therapyOral Surg Oral Med Oral Pathol Oral Radiol Endod20101094 488 49520156694
   PubMed Web of Science ®Google Scholar
• Jabra-RizkMAJohnsonJKForrestGMankesKMeillerTFVeneziaRAPrevalence of Candida dubliniensis fungemia at a large teaching hospitalClin Infect Dis2005417 1064 106716142677
   PubMed Web of Science ®Google Scholar
• SullivanDJMoranGPPinjonEComparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicansFEMS Yeast Res200444–5 369 37614734017
   PubMed Web of Science ®Google Scholar
• YanZYoungALHuaHXuYMultiple oral Candida infections in patients with Sjogren’s syndrome–prevalence and clinical and drug susceptibility profilesJ Rheumatol20113811 2428 243121844143
   PubMed Web of Science ®Google Scholar
• SilvaSHenriquesMMartinsAOliveiraRWilliamsDAzeredoJBiofilms of non-Candida albicans Candida species: quantification, structure and matrix compositionMed Mycol2009477 681 68919888800
   PubMed Web of Science ®Google Scholar
• UppuluriPPierceCGLópez-RibotJLCandida albicans biofilm formation and its clinical consequencesFuture Microbiol2009410 1235 123719995182
   PubMed Web of Science ®Google Scholar
• MukherjeePKChandraJCandida biofilm resistanceDrug Resist Updat200474–5 301 30915533767
   PubMed Web of Science ®Google Scholar
• DonlanRMCostertonJWBiofilms: survival mechanisms of clinically relevant microorganismsClin Microbiol Rev2002152 167 19311932229
   PubMed Web of Science ®Google Scholar
• MahTFO’TooleGAMechanisms of biofilm resistance to antimicrobial agentsTrends Microbiol200191 34 3911166241
   PubMed Web of Science ®Google Scholar
• MukherjeePKChandraJKuhnDMGhannoumMAMechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterolsInfect Immun2003718 4333 434012874310
   PubMed Web of Science ®Google Scholar
• DenningDWEchinocandins: a new class of antifungalJ Antimicrob Chemother2002496 889 89112039879
   PubMed Web of Science ®Google Scholar
• NettJLincolnLMarchilloKPutative role of β-1,3 glucans in Candida albicans biofilm resistanceAntimicrob Agents Chemother2007512 510 52017130296
   PubMed Web of Science ®Google Scholar
• GulatiMNobileCJCandida albicans biofilms: development, regulation, and molecular mechanismsMicrobes Infect2016185 310 32126806384
   PubMed Web of Science ®Google Scholar
• LangfordMLHasimSNickersonKWAtkinALActivity and toxicity of farnesol towards Candida albicans are dependent on growth conditionsAntimicrob Agents Chemother2010542 940 94219933803
   PubMed Web of Science ®Google Scholar